Analystreport

SpringWorks Therapeutics (NASDAQ: SWTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $58.00 price target on the stock.

SpringWorks Therapeutics, Inc. - common stock  (SWTX) 
Last springworks therapeutics, inc. - common stock earnings: 3/12 04:30 pm Check Earnings Report